<DOC>
	<DOC>NCT00703235</DOC>
	<brief_summary>Diabetic macular edema is a common cause of visual loss among diabetic patients. Studies have demonstrated the role of vascular endothelial growth factor (VEGF) in the pathogenesis of edema. This study designed to evaluate the effect of Intravitreal injection of a recombinant monoclonal anti-VEGF antibody, Bevacizumab, for treatment of diabetic macular edema.</brief_summary>
	<brief_title>Intravitreal Bevacizumab for Diabetic Macular Edema</brief_title>
	<detailed_description />
	<mesh_term>Macular Edema</mesh_term>
	<mesh_term>Edema</mesh_term>
	<mesh_term>Diabetic Retinopathy</mesh_term>
	<mesh_term>Bevacizumab</mesh_term>
	<criteria>Diabetes mellitus Clinically significant macular edema Possibility of performing macular OCT Consent of patient for inclusion in the study History of macular photocoagulation in less than 6 months of inclusion in the study Necessity of surgical intervention Rejection of the remaining in the study by patient</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2008</verification_date>
</DOC>